Porfimer Sodium
- Generic Name
- Porfimer Sodium
- Brand Names
- Photofrin
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 87806-31-3
- Unique Ingredient Identifier
- Y3834SIK5F
- Background
The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.
- Indication
临床上用于对不能用手术及其他根治疗法的肺、子宫颈癌或需非手术治疗的患者，在内镜下能观察到病灶的全貌、可能进行激光照射的下列疾病：早期肺癌（0期或Ⅰ期）、浅表性食管癌、浅表性早期胃癌、宫颈癌初期及发育异常。
- Associated Conditions
- Barrett's Esophagus, Esophageal Cancer, Completely obstructive Non-small cell lung cancer, Microinvasive endobrachial Non-small cell lung cancer, Partially obstructive Non-small cell lung cancer
- Associated Therapies
- -
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
- Conditions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00003923
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
- Conditions
- First Posted Date
- 2003-10-22
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00002935
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00054002
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Colorado Health Foundation
- Target Recruit Count
- 270
- Registration Number
- NCT00003788
- Locations
- 🇨🇦
St. Michael's Hospital-Annex, Toronto, Ontario, Canada
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Rocky Mountain Neurological Associates, Englewood, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.